Purple Biotech (PPBT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Purple Biotech has successfully closed a $2.8 million registered direct offering of American Depositary Shares, with H.C. Wainwright & Co. acting as the exclusive placement agent. The funds will be used to advance the development of their oncology therapeutic candidates and support general corporate activities. Investors interested in biotech innovations and oncology therapies might find opportunities with Purple Biotech’s continued progress in overcoming tumor immune evasion and drug resistance.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.